Independent rankings of compounded and brand-name GLP-1 (semaglutide and tirzepatide) telehealth providers serving Tulsa, Oklahoma residents in 2026. Tulsa residents have access to all major telehealth GLP-1 providers under Oklahoma prescribing rules.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Telehealth GLP-1 access in Tulsa, Oklahoma
Telehealth GLP-1 prescribing is permitted statewide in Oklahoma under the standard physician-patient relationship rules. Compounded semaglutide and tirzepatide are usually prepared by state-licensed 503A compounding pharmacies (USP <797> sterile compounding) and shipped directly to Tulsa addresses. FDA proposed in April 2026 not to add either drug to the 503B bulks list. There is no in-person visit requirement at any of the providers reviewed on this page; an asynchronous or synchronous telehealth consultation with a licensed clinician is the only intake step.
Compounded GLP-1 prescriptions shipped to Tulsa usually come from out-of-state 503A pharmacies; ask which pharmacy fills yours and check its license. Tulsa residents do not need a local compounding pharmacy — the medications are prepared at the dispensing pharmacy and shipped to the patient's address under refrigerated logistics.
Yes. All major telehealth GLP-1 providers ship to Tulsa addresses under Oklahoma prescribing rules.
How much does GLP-1 telehealth cost in Tulsa?
NexLife, our editor’s pick, charges $95 a month for compounded semaglutide and $115 for compounded tirzepatide on 12-month plans, the same at every dose (read November 6, 2026); Mondae publishes lower month-to-month prices, and Eden Health a lower semaglutide price.
Is compounded semaglutide legal in Oklahoma?
Yes, when a state-licensed 503A pharmacy fills a valid, patient-specific prescription, though it is not FDA-approved. In April 2026 FDA proposed not to add semaglutide to the 503B bulks list; no final decision had been published as of October 15, 2026. It is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus.